Close Menu

NEW YORK (GenomeWeb) – Inivata said today that Medicare administrative contractor Palmetto GBA has finalized its draft local coverage determination (LCD) for the company's liquid biopsy lung cancer test, InVisionFirst-Lung.

The policy, which becomes effective April 8, provides specific coverage for the test for all fee-for-service Medicare patients in the US with advanced (Stage IIIB/IV) NSCLC who meet specific clinical criteria.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports that the CDC's SARS-CoV-2 test issues reflect earlier ones it had with Zika virus testing.

NPR writes that even with thousands of new COVID-19 papers, each should be evaluated based on its own quality.

Researchers traced a gene cluster linked to COVID-19 severity to Neanderthals, the New York Times reports.

In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.